From “Pharmacy of the World” to Global Innovator: Why India Must Reinvent Its Drug Regulations

India’s pharmaceutical industry has long been celebrated as the “pharmacy of the world,” supplying affordable medicines across continents. Yet, behind this success lies a regulatory framework that is struggling to keep pace with the sector’s rapid evolution. If India truly aims to lead not just in volume but in innovation and quality, reforming drug regulations is no longer optional—it is urgent.

An Outdated Legal Backbone

At the heart of the issue is the Drugs and Cosmetics Act of 1940, a law crafted in a vastly different era. When it was introduced, India had little domestic pharmaceutical capacity and relied heavily on imports. Today, the country is a global manufacturing powerhouse, yet it continues to operate under a framework designed for colonial realities.

This mismatch creates inefficiencies, regulatory gaps, and inconsistencies that hinder innovation. Modern drug development—especially in biologics, precision medicine, and complex generics—demands a dynamic and adaptive regulatory environment, not a static one rooted in the past.

The Cost of Fragmented Regulation

India’s regulatory system is often criticized for being fragmented between central and state authorities. This leads to uneven enforcement and varying standards across regions. Recent actions—such as the crackdown on unapproved drug combinations—highlight both the scale of the problem and the need for tighter oversight.

Moreover, the influx of generic drugs following patent expiries has raised concerns about quality control, misuse, and market confusion. Without strong and consistent regulatory enforcement, the credibility of India’s pharmaceutical exports could be at risk.

Regulation Must Evolve with Innovation

India is increasingly positioning itself as a hub for pharmaceutical innovation. Government initiatives like strengthening the Central Drugs Standard Control Organisation (CDSCO) and investing in biopharma signal a clear intent to move up the value chain.

Recent regulatory amendments have also attempted to accelerate drug approvals and streamline clinical trial processes, reducing timelines and improving efficiency.

However, speed alone is not enough. A robust regulatory system must strike a balance between faster approvals and uncompromising safety standards. As global pharmaceutical leaders have pointed out, India must ensure that accelerated processes do not dilute quality.

Beyond Compliance: Building a Culture of Collaboration

One of the most critical shifts India needs is cultural rather than procedural. Regulatory reform cannot remain a top-down exercise driven solely by government directives. Instead, it must become a continuous, collaborative process involving industry, academia, healthcare professionals, and patients.

For instance, recent rules requiring manufacturers to report post-approval changes in drug composition and processes reflect a move toward greater transparency and accountability.

But true transformation requires deeper engagement—regular stakeholder consultations, real-time feedback mechanisms, and adaptive policymaking that evolves with scientific advancements.

The Global Opportunity—and Responsibility

India stands at a pivotal moment. With increasing global demand for affordable and high-quality medicines, the country has a unique opportunity to shape the future of global healthcare. Initiatives like Biopharma Shakti aim to boost domestic innovation and position India as a leader in next-generation therapeutics.

However, global leadership comes with responsibility. International markets expect not just affordability but also stringent quality, transparency, and regulatory reliability. Aligning Indian standards with global benchmarks is essential to maintain trust and expand market access.

The Road Ahead

Improving drug regulations in India is not about incremental tweaks—it requires a fundamental rethink. The focus must shift from reactive policymaking to proactive governance. Regulations should be:

• Dynamic, evolving with scientific and technological advancements
• Harmonized, ensuring consistency across states and agencies
• Transparent, building trust among stakeholders and consumers
• Collaborative, incorporating diverse perspectives in decision-making

India’s pharmaceutical journey is already remarkable, but its next chapter depends on how effectively it reforms its regulatory ecosystem.

If India is serious about becoming a global leader—not just in producing medicines, but in shaping the future of healthcare—it must treat regulatory reform as an ongoing mission, not a one-time fix.